Neoadjuvant treatment for breast cancer before surgery
Part of Cancer, Skin clinical trials.
This trial tests a treatment given before breast surgery to shrink breast cancer and improve outcomes based on your tumor type. Your eligibility depends on tumor size/stage, hormone and HER2 markers, and overall health checks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older with breast cancer on one side (unilateral), confirmed by biopsy
- Your tumor is larger than 2 cm or you have breast cancer spread to nearby lymph nodes
- You have test results for ER, PR, HER2, and Ki-67, and your cancer type fits one of the trial groups (triple-negative, hormone-like “luminal,” or HER2-positive)
- You have not had any prior treatment for this breast cancer (no chemo, radiation, targeted therapy, or hormone therapy yet)
- Your body is healthy enough for treatment: performance score 0–1, normal heart function (LVEF ≥55%), and acceptable blood/organ lab tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 4 study tests an additional (adjuvant) treatment for breast cancer after surgery and standard follow-up care. It may help lower the chance the cancer comes back, but you must match specific tumor and body-chemistry requirements to join.
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial tests giving chemotherapy before surgery to shrink breast tumors, which may make surgery easier or allow breast-conserving options. It is for adults with invasive breast cancer that has not spread to distant organs.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.